Ivan Chebib

Ivan Chebib

Auto-generated profile, based on publicly available information

Ivan Chebib

Department of Pathology Massachusetts General Hospital and Harvard Medical School Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Science Advances
Verified
Journal Article
Open access
RSRajendran Sanalkumar
Rajendran Sanalkumar
RDRui Dong
Rui Dong
LLLukuo Lee
Lukuo Lee
YXYu-Hang Xing
Yu-Hang Xing
SISowmya Iyer
Sowmya Iyer
NRNicolò Riggi
Nicolò Riggi
Cell fate transitions observed in embryonic development involve changes in three-dimensional genomic organization that provide proper lineage specification. Whether similar events occur within tumor cells and contribute to cancer evolution remains largely unexplored. We modeled this process in the pediatric cancer Ewing sarcoma and investigated high-resolution looping and large-scale nuclear conformation changes associated with the oncogenic fusion protein EWS-FLI1. We show that chromatin interactions in tumor cells are dominated by highly connected looping hubs centered on EWS-FLI1 binding sites, which directly control the activity of linked enhancers and promoters to establish oncogenic expression programs. Conversely, EWS-FLI1 depletion led to the disassembly of these looping networks and a widespread nuclear reorganization through the establishment of new looping patterns and large-scale compartment configuration matching those observed in mesenchymal stem cells, a candidate Ewing sarcoma progenitor. Our data demonstrate that major architectural features of nuclear organization in cancer cells can depend on single oncogenes and are readily reversed to reestablish latent differentiation programs.

13 December 2019 in Sarcoma
Verified
Journal Article
Open access
PDF file
RMRuoyu Miao
Ruoyu Miao
ECEdwin Choy
Edwin Choy
KRKevin A. Raskin
Kevin A. Raskin
JSJoseph H. Schwab
Joseph H. Schwab
GNGunnlaugur Petur Nielsen
Gunnlaugur Petur Nielsen
YCYen-Lin E. Chen
Yen-Lin E. Chen
Background. Dedifferentiated chondrosarcomas (DDCSs) are highly malignant tumors with a dismal prognosis and present a significant challenge in clinical management. Methods. In an IRB approved retrospective protocol, we identified 72 patients with DDCS treated at our institution between 1993 and 2017 and reviewed clinicopathological characteristics, treatment modalities, and outcomes to analyze prognostic factors. Results. Femur (44.4%), pelvis (22.2%), and humerus (12.5%) were most commonly involved sites. Twenty-three patients (31.9%) presented with distant metastasis, and 3 (4.2%) of them also had regional lymph node involvement. The median overall survival (OS) was 13.9 months. On multivariate analysis, pathological fracture, larger tumor size, lymph node involvement, metastasis at diagnosis, extraosseous extension, and undifferentiated pleomorphic sarcoma component correlated with worse OS, whereas surgical resection and chemotherapy were associated with improved OS. For progression-free survival (PFS), pathological fracture and metastasis at diagnosis showed increased risk, while chemotherapy was associated with decreased risk. Among patients who received chemotherapy, doxorubicin and cisplatin were significantly associated with improved PFS but not OS. Among patients without metastasis at diagnosis, 17 (34.7%) developed local recurrence. Thirty-one (63.3%) developed distant metastases at a median interval of 18.1 months. On multivariate analysis, R1/R2 resection was related with local recurrence, while macroscopic dedifferentiated component was associated with distant metastasis. Conclusions. The prognosis of DDCS is poor. Complete resection remains a significant prognostic factor for local control. Chemotherapy with doxorubicin and cisplatin seems to have better PFS. More prognostic, multicenter trials are warranted to further explore the effectiveness of chemotherapy in selected DDCS patients.

1 April 2021 in World Neurosurgery
Verified
Journal Article
Closed access
KYKaiyun Yang
Kaiyun Yang
KRKesava Reddy
Kesava Reddy
ICIvan Chebib
Ivan Chebib
RHRobert Hammond
Robert Hammond
JLJian-Qiang Lu
Jian-Qiang Lu

8 January 2015 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
ICIvan Chebib
Ivan Chebib
FHFrancis J. Hornicek
Francis J. Hornicek
GNG. Petur Nielsen
G. Petur Nielsen
VDVikram Deshpande
Vikram Deshpande

4 January 2018 in Histopathology
Verified
Journal Article
Closed access
PDF file
ICIvan Chebib
Ivan Chebib
CCConnie Y Chang
Connie Y Chang
JSJoseph H Schwab
Joseph H Schwab
DKDarcy A Kerr
Darcy A Kerr
VDVikram Deshpande
Vikram Deshpande
GNG Petur Nielsen
G Petur Nielsen

19 May 2016 in Histopathology
Verified
Journal Article
Closed access
PDF file
ICIvan Chebib
Ivan Chebib
ARAndrew E Rosenberg
Andrew E Rosenberg
CFChristopher D. M. Fletcher
Christopher D. M. Fletcher
DRDaniel I Rosenthal
Daniel I Rosenthal
FHFrancis J. Hornicek
Francis J. Hornicek
GNG. Petur Nielsen
G. Petur Nielsen